Recent detectable viral loads among adults living with HIV in the Asia-Pacific between 2015 to 2020



Maylin Palatino¹, Dhanushi Rupasinghe², Alvina Widhani³, Ngoc Chi⁴, I Ketut Agus Somia⁵, Nagalingeswaran Kumarasamy⁶, Suwimon Khusuwan⁷, Vohith Khol⁸, Man Po Lee⁹, Sasisopin Kiertiburanakul¹⁰, Thach Ngoc Pham¹¹, Sanjay Pujari¹², Anchalee Avihingsanon¹³, Jun Yong Choi¹⁴, Romanee Chaiwarith¹⁵, Yu-Jiun Chan¹⁶, Iskandar Azwa¹⁷, Rossana Ditangco¹⁸, Rohidas T Borse¹⁹, Oon Tek NG²⁰, Junko Tanuma²¹, Fujie Zhang²², Yasmin Gani²³, Jeremy Ross²⁴, and Awachana Jiamsakul², on behalf of the International Epidemiology Databases to Evaluate AIDS (IeDEA) Asia-Pacific

¹University of Maryland, USA, ²The Kirby Institute, UNSW Sydney, Australia, ³Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, ⁴Bach Mai Hospital, Vietnam, ⁵Faculty of Medicine Udayana University - Prof. Dr. I.G.N.G. Ngoerah Hospital, Indonesia, ⁶CART CRS, Voluntary Health Services, India, ⁷Chiangrai Prachanukroh Hospital, Thailand
⁸National Center for HIV/AIDS, Dermatology & STDs, Cambodia, ⁹Queen Elizabeth Hospital, Hong Kong SAR, ¹⁰Mahidol University, Thailand, ¹¹National Hospital for Tropical Diseases, Vietnam, ¹²Institute of Infectious Diseases, India, ¹³Faculty of Medicine, Chulalongkorn University, Thailand, ¹⁴Yonsei University College of Medicine, South Korea, ¹⁵Chiang Mai University, Thailand, ¹⁶Taipei Veterans General Hospital, Taiwan, ¹⁷University of Malaya, Malaysia, ¹⁸Research Institute for Tropical Medicine, Philippines, ¹⁹BJ Government Medical College and Sassoon General Hospital, India, ²⁰Tan Tock Seng Hospital, Singapore, ²¹National Center for Global Health and Medicine, Japan, ²²Capital Medical University, China, ²³Hospital Sungai Buloh, Malaysia, ²⁴TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand

BACKGROUND

RESULTS

A proportion of people living with HIV (PLWH) continue to have detectable viral load (VL) while on robust antiretroviral therapy (ART) regimens and risk onward HIV transmission. We aimed to estimate the proportion and factors associated with having a detectable VL between 2015 and 2020 in two Asia-Pacific HIV observational cohorts.

Figure 1. Asia-Pacific countries and territories included in TAHOD and TAHOD-LITE cohorts



METHODS


This analysis included available data from adult PLWH enrolled in two prospective observational cohort studies of IeDEA Asia-Pacific: the TREAT Asia HIV Observational Database (TAHOD) and TAHOD Low Intensity Transfer (TAHOD-LITE) cohorts (Figure 1). Eligible participants were on ART for \geq 1 year, in follow-up between 2015 and 2020, and with \geq 1 VL measurement during the follow-up period.

Detectable VL was defined as having ≥ 1 VL measurement ≥ 50 copies/mL during 2015-2020. The proportion with detectable VL during the follow-up period and the distribution of VL measurements per year were obtained. The proportions with viral blips, i.e., detectable VL measurements followed by a VL ≤ 50 copies/mL on retesting within 6 months, were likewise computed. Factors associated with detectable VL were analyzed using repeated measures logistic regression. Of the 20,765 PLWH included, the majority were male (64%) and had heterosexual contact as their mode of HIV exposure (72%). The median age was 36 (Table 1).

Characteristics	Total PLWH	PLWH who never had detectable VL	PLWH who ever had detectable VL (≥50 copies/mL)
Total, N (%)	20,765 (100)	14,727 (71)	6,038 (29
Sex, N (%) Males Females	13,376 (64) 7,389 (36)	9,290 (63) 5,437 (37)	4,086 (68 1,952 (32
Age (years) at ART initiation, median (IQR)	36 (30-43)	36 (30-43)	36 (30-42
HIV Exposure, N (%) Heterosexual contact MSM Injecting drug use Other/Unknown	15,012 (72) 2,985 (14) 755 (4) 2,013 (10)	10,454 (71) 2,322 (16) 612 (4) 1,339 (9)	4,558 (75 663 (11 143 (2 674 (11
CD4 cell count (cells/µl) at ART initiation, median (IQR)	168 (59-287)	174 (54-299)	158 (67-262
Viral Load (log ₁₀ (copies/mL)) at ART initiation, median (lQR)	2 (2-3)	2 (2-3)	2 (2-2
Hepatitis B surface antigen, N (%) Negative Ever positive Not reported	13,682 (66) 1,451 (7) 5,632 (27)	10,388 (70) 1,138 (8) 3,201 (22)	3,294 (55 313 (5 2,431 (40
Hepatitis C antibody, N (%) Negative Ever positive Not reported	12,802 (62) 1,418 (7) 6,545 (31)	10,405 (68) 1,131 (8) 3,551 (24)	2,757 (45 287(5 2,994 (50
World Bank country income, N (%) Lower Middle Upper Middle High	10,215 (49) 7,514 (36) 3,036 (15)	6,035 (41) 6,410 (44) 2,282 (16)	4,180 (69 1,104 (18 754 (13

During the study period, 6,038 (29%) had \geq 1 detectable VL. Of these, 2,881 (48%) had VL measurements between 50 and <200 copies/mL, 684 (11%) between 200 and <1000, 495 (8%) between 1000 and <5000, and 1,978 (33%) \geq 5000 copies/mL. The highest and lowest proportions with VL measurements \geq 5,000 copies/mL were in years 2018 (37%) and 2015 (25%), respectively (Figure 2). The proportions with viral blips varied over time: 2015 (10%), 2016 (11%), 2017 (13%), 2018 (17%), 2019 (21%), and 2020 (14%).





The factors associated with decreased odds of detectable VL included female sex compared to males; older age compared to \leq 30 years; male-male sex and injecting drug use compared to heterosexual contact as mode of HIV exposure; non-nucleoside reverse transcriptase inhibitor-based ART (NNRTI) compared to integrase strand transfer inhibitor (INSTI)-based regimens; hepatitis B or hepatitis C co-infection, higher CD4 count compared to CD4 <200 cells/µL; and higher country income compared to lower-middle. Detectable VL was more likely among those on protease inhibitor-based ART (Figure 3).

Figure 3. Factors associated with having detectable viral load (≥50 copies/mL) using repeated measures

Covariate		Adj OR (95% CI)
Sex		
Female vs Male	-	0.84 (0.78, 0.90)
Time-updated age (years)	1	
31-40 vs at most 30	-#-	0.68 (0.60, 0.76)
41-50 vs at most 30		0.56 (0.49, 0.63)
at least 51 vs at most 30	+	0.43 (0.38, 0.49)
HIV mode of exposure	1	
MSM vs heterosexual contact		0.86 (0.75, 0.97)
Injecting drug use vs heterosexual contact		0.65 (0.52, 0.83)
Other/Unknown vs heterosexual contact	-	0.58 (0.52, 0.65)
Time-updated ARV Regimen		
PI-based vs INSTI-based		
NNRTI-based vs INSTI-based	-	0.47 (0.43, 0.52)
Other/No ART vs INSTI-based		0.99 (0.78, 1.25)
HBV surface antigen		
Ever positive vs negative		0.80 (0.70, 0.92)
HCV antibody		
Ever positive vs negative		0.81 (0.69, 0.97)
Time-updated CD4 (cells/microliter)	1	
200-350 vs <200	+	0.34 (0.30, 0.38)
351-500 vs <200		0.20 (0.18, 0.23)
>500 vs <200		0.17 (0.15, 0.18)
World Bank country income		
Upper Middle vs lower Middle		0.22 (0.20, 0.24)
High vs lower Middle		0.36 (0.32, 0.40)
Time-updated calendar year		
2016 vs 2015	-	0.81 (0.76, 0.86)
2017 vs 2015		0.60 (0.56, 0.64)
2018 vs 2015		0.39 (0.36, 0.42)
2019 vs 2015		0.37 (0.34, 0.40)
2020 vs 2015	.	0.34 (0.31, 0.38)
	0.2 0.5 0.8 1	
	Adjusted odds r	atio

CONCLUSIONS

Almost one third of PLWH in our analysis had detectable VL between 2015 and 2020, of these, a third had VL measurements ≥5,000 copies/mL, indicating the need for strengthening life-long adherence counselling and follow-up, particularly among those with increased odds of detectable VL.

Acknowledgements

The TREAT Asia HIV Observational Database is an initiative of TREAT Asia, a program of amfAR, The Foundation for AIDS Research, with support from the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, the *Eunice Kennedy Shriver* National Institute on Drug Abuse, the National Heart, Lung, and Blood Institute, the National Institute of Mental Institute of Mental Health, the National Institute on Drug Abuse, the National Institute is funded by the Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, UNSW Sydney. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the governments or institutions mentioned above.

The TREAT Asia HIV Observational Database: V Khol*, V Ouk, C Pov, National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; FJ Zhang*, HX Zhao, N Han, Beijing Ditan Hospital, Capital Medical University, Beijing, China; MP Lee*, PCK Li, TS Kwong, TH Li, Queen Elizabeth Hospital, Hong Kong SAR; N Kumarasamy*, C Ezhilarasi, Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS-Infectious Diseases Medical Centre, VHS, Chennai, India; S Pujari*, K Joshi, S Gaikwad, A Chitalikar, Institute of Infectious Diseases, Pune, India; RT Borse*, V Mave, I Marbaniang, S Nimkar, BJ Government Medical College and Sassoon General Hospital, Pune, India; IKA Somia*, TP Merati, AAS Sawitri, F Yuliana, Faculty of Medicine Udayana University - Prof.Dr.I.G.N.G. Ngoerah Hospital, Bali, Indonesia; E Yunihastuti*, A Widhani, S Maria, TH Karjadi, Faculty of Medicine Universits Indonesis. Or. Cipto Mangunkusumo General Hospital, Jakara, Indonesia; I Tanuma*, S Oka, T Nishijima, National Center for Global Health and Medicine, Tokyo, Japan; YC Loh*, Na S, JM Kim, Division of Infectious Diseases, Department of Internal Medicine, Yonea; VI Gani*, NB Rudi, Hospital Suloh, Surgai Bluoh, Surgai Bluoh, Surgai Bluoh, Surgai Bluoh, Surgai Suloh, Xalaysia; I Zawa*, A Kamarutzaman, SF Syed Omar, S Ponnampalavanar, University Malaya Medical Centre, Kuala Lumpur, Malaysia; R Ditangoc*, MK Pane; Nesvea: A Institute for Tropical Medicine, Muntinlupa City, Philippines; YJ Cha*, HP Chen, PC Wu, E Ke, Taipei Veterans General Hospital, Taipei, Taipei







